- Salarius Pharmaceuticals (SLRX, Financial) announces progress in Phase 1/2 clinical study of seclidemstat for cancer treatment.
- Recent studies validate seclidemstat's role in inhibiting LSD1 crucial for potential cancer therapies.
- Salarius advances merger with Decoy Therapeutics, aiming for strategic growth and innovation.
Salarius Pharmaceuticals (SLRX) has reported significant developments for its LSD1 inhibitor, seclidemstat (SP-2577). Two newly published animal studies provide supporting evidence of seclidemstat's role in inhibiting LSD1, a key target in oncology, highlighting its potential effectiveness in treating cancer.
The studies, appearing in peer-reviewed journals, underscore seclidemstat's promising mechanism in addressing cancers such as myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The drug is currently under evaluation in a Phase 1/2 clinical trial at the MD Anderson Cancer Center, with updates anticipated by the end of 2025.
In addition, Salarius continues to progress with its planned merger with Decoy Therapeutics, expected to complete the transaction to form a new entity named Decoy Therapeutics. This strategic move is poised to leverage Decoy's IMP3ACTâ„¢ platform, potentially enhancing the combined pipeline's breadth in respiratory viruses and gastrointestinal oncology.
Seclidemstat, a first-in-class orally bioavailable LSD1 inhibitor, represents a significant asset in Salarius' pipeline, targeting firstly validated hematologic and solid tumor applications. The ongoing clinical study at MD Anderson is aimed at expanding treatment options for MDS and CMML patients, conditions with high unmet medical needs.
